1. Berger, M., Gray, J. A. & Roth, B. L. The expanded biology of serotonin. Annu. Rev. Med. 60, 355–366 (2009).

2. Roth, B. L., Willins, D. L., Kristiansen, K. & Kroeze, W. K. 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacol. Ther. 79, 231–257 (1998).

3. Nichols, D. E. & Nichols, C. D. Serotonin receptors. Chem. Rev. 108, 1614–1641 (2008).

4. Branchek, T., Adham, N., Macchi, M., Kao, H. T. & Hartig, P. R. [3H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and [3H] ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor. Mol. Pharmacol. 38, 604–609 (1990).

5. Mestre, T. A., Zurowski, M. & Fox, S. H. 5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders. Expert Opin. Investig. Drugs 22, 411–421 (2013).

6. Aznar, S. & Hervig, M. E. The 5-HT2A serotonin receptor in executive function: implications for neuropsychiatric and neurodegenerative diseases. Neurosci. Biobehav. Rev. 64, 63–82 (2016).

7. Meltzer, H. Y. & Massey, B. W. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr. Opin. Pharmacol. 11, 59–67 (2011).

8. Kroeze, W. K. et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28, 519–526 (2003).

9. Roth, B. L., Sheffler, D. J. & Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug. Discov. 3, 353–359 (2004).

10. Muench, J. & Hamer, A. M. Adverse effects of antipsychotic medications. Am. Fam. Physician 81, 617–622 (2010).

11. Weston-Green, K., Huang, X. F. & Deng, C. Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor. CNS Drugs 27, 1069–1080 (2013).

12. Uchiyama, S., Ozaki, Y., Satoh, K., Kondo, K. & Nishimaru, K. Effect of sarpogrelate, a 5-HT2A antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study. Cerebrovasc. Dis. 24, 264–270 (2007).

13. Meltzer, H. Y. & Roth, B. L. Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. J. Clin. Invest. 123, 4986–4991 (2013).

14. Vanover, K. E. & Davis, R. E. Role of 5-HT2A receptor antagonists in the treatment of insomnia. Nat. Sci. Sleep 2, 139–150 (2010).

15. Peng, Y. et al. 5-HT2C receptor structures reveal the structural basis of GPCR polypharmacology. Cell 172, 719-+ (2018).

16. Wacker, D. et al. Structural features for functional selectivity at serotonin receptors. Science 340, 615–619 (2013).

17. Yin, W. et al. Crystal structure of the human 5-HT1B serotonin receptor bound to an inverse agonist. Cell Discov. 4, 12 (2018).

18. Wang, S. et al. Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone. Nature 555, 269–273 (2018).

19. Shimamura, T. et al. Structure of the human histamine H1 receptor complex with doxepin. Nature 475, 65–70 (2011).

20. Ballesteros, J. A. & Weinstein, H. Integrated methods for the construction of three dimensional models and computational probing of structure–function relations in G protein-coupled receptors. Methods Neurosci. 25, 366–428 (1995).

21. Isberg, V. et al. Generic GPCR residue numbers - aligning topology maps while minding the gaps. Trends Pharmacol. Sci. 36, 22–31 (2015).

22. Roth, B. L., Lopez, E., Patel, S. & Kroeze, W. K. The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches? The Neuroscientist 6, 252–262 (2000).

23. Michino, M. et al. What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands? Pharmacol. Rev. 67, 198–213 (2015).

24. Mathis, M. V. et al. The US Food and Drug Administration’s perspective on the new antipsychotic pimavanserin. J. Clin. Psychiatry 78, e668–e673 (2017).

25. Hacksell, U., Burstein, E. S., McFarland, K., Mills, R. G. & Williams, H. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson’s psychosis. Neurochem. Res. 39, 2008–2017 (2014).

26. Meltzer, H. Y., Matsubara, S. & Lee, J. C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 Pki values. J. Pharmacol. Exp. Ther. 251, 238–246 (1989).

27. Chu, R. et al. Redesign of a four-helix bundle protein by phage display coupled with proteolysis and structural characterization by NMR and X-ray crystallography. J. Mol. Biol. 323, 253–262 (2002).

28. Roth, C. B., Hanson, M. A. & Stevens, R. C. Stabilization of the human beta2-adrenergic receptor TM4TM3TM5 helix interface by mutagenesis of Glu122(3.41), a critical residue in GPCR structure. J. Mol. Biol. 376, 1305–1319 (2008).

29. Yasuda, S. et al. Hot-spot residues to be mutated common in G protein-coupled receptors of class A: identification of thermostabilizing mutations followed by determination of three-dimensional structures for two example receptors. J. Phys. Chem. B 121, 6341–6350 (2017).

30. Yamashita, K., Hirata, K. & Yamamoto, M. KAMO: towards automated data processing for microcrystals. Acta Crystallog. D Struct. Biol. 74, 441–449 (2018).

31. Foadi, J. et al. Clustering procedures for the optimal selection of data sets from multiple crystals in macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 69, 1617–1632 (2013).

32. Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132 (2010).

33. Kabsch, W. Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr. D Biol. Crystallogr. 66, 133–144 (2010).

34. Mccoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).

35. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Struct. Biol. 66, 213–221 (2010).

36. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).

37. Davis, I. W. et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35, W375–W383 (2007).

38. Friesner, R. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47, 1739–1749 (2004).

39. Inoue, A. et al. TGF alpha shedding assay: an accurate and versatile method for detecting GPCR activation. Nat. Methods 9, 1021–1029 (2012).

40. Schrage, R. et al. The experimental power of FR900359 to study Gq-regulated biological processes. Nat. Commun. 6, 10156 (2015).

41. Takasaki, J. et al. A novel G alpha(q/11)-selective inhibitor. J. Biol. Chem. 279, 47438–47445 (2004).

42. Egan, C. T., Herrick-Davis, K. & Teitler, M. Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs. J. Pharmacol. Exp. Ther. 286, 85–90 (1998).